We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The healthcare industry, led by biotech and pharmaceutical
companies, garnered a record share of the venture capital (VC) dollars last
year, according to a recent report.
Pfizer has inked a deal to acquire Idun Pharmaceuticals, a San Diego-based biopharmaceutical
firm that owns more than 150 patents covering drug targets, new chemical entities,
drug-screening assays, diagnostics and antibodies.
Privately held biotech company Sciona Inc. has closed on its third round of
financing, its first since relocating from the United Kingdom to Boulder earlier
this year.
Nautilus Biotech a private protein pharmaceutical company announced the completion
of a Euro 7.25 million round of financing with a syndicate led by Auriga Partners.
Drug development firm Point Therapeutics said recently it plans to sell 3.65
million of its common shares at $4.50 each in a direct offering, primarily to
institutional investors.
Debiopharm S.A., the independent drug development company specializing in oncology,
endocrinology and niche products, has announced that it has purchased all the
outstanding shares of H3 Pharma from Montreal-based Societe Generale de Financement
du Quebec (SGF).
Discovery Partners International has announced that it has signed a binding
letter of intent, subject to confirmatory due diligence, to acquire Biofrontera
Discovery GmbH, based in Heidelberg, Germany, the natural products drug discovery
subsidiary of Biofrontera AG, a privately held specialty pharma business.